BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16957557)

  • 1. Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?
    Aw TJ; Liew D; Tofler GH; Schneider HG; Morel-Kopp MC; Billah B; Krum H
    J Hypertens; 2006 Oct; 24(10):1979-84. PubMed ID: 16957557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
    Fredy J; Diggins DA; Morrill GB
    Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
    Hinz B; Dormann H; Brune K
    Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
    Wolfe F; Zhao S; Pettitt D
    J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
    Wang BH; Bertucci MC; Ma JY; Adrahtas A; Cheung RY; Krum H
    Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):912-8. PubMed ID: 20497423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis.
    Derici U; Goker B; Ayerden-Ebinc F; Altok KR; Erten Y; Haznedaroglu S; Aydin M; Arinsoy T; Sindel S
    Int J Tissue React; 2005; 27(2):69-73. PubMed ID: 16035651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
    Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment.
    Horackova M; Schück O; Komers R; Charvat J; Teplan V; Kvapil M
    Int J Clin Pharmacol Ther; 2005 Sep; 43(9):413-9. PubMed ID: 16163893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
    Smugar SS; Schnitzer TJ; Weaver AL; Rubin BR; Polis AB; Tershakovec AM
    Curr Med Res Opin; 2006 Jul; 22(7):1353-67. PubMed ID: 16834834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
    Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
    Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased systolic blood pressure with rofecoxib in congenital furosemide-like salt loss.
    Kömhoff M; Klaus G; Nazarowa S; Reinalter SC; Seyberth HW
    Nephrol Dial Transplant; 2006 Jul; 21(7):1833-7. PubMed ID: 16554326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
    Whelton A; White WB; Bello AE; Puma JA; Fort JG;
    Am J Cardiol; 2002 Nov; 90(9):959-63. PubMed ID: 12398962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
    Zhu FS; Chen XM; Wang YJ; Zhang X; Feng JX
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):186-8. PubMed ID: 17649633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory effects of selective COX-2 inhibitors.
    Süleyman H; Demircan B; Karagöz Y; Oztaşan N; Süleyman B
    Pol J Pharmacol; 2004; 56(6):775-80. PubMed ID: 15662090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
    Becker RV; Burke TA; McCoy MA; Trotter JP
    Clin Ther; 2003 Feb; 25(2):647-62. PubMed ID: 12749519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
    Rahme E; Hunsche E; Toubouti Y; Chabot I
    Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.